Functional Gene Tests and Total Bacteria Count

miyeloleykozu with moderate splenomegaly with WBC count to 200 000 in 1 ml of blood - 4 - 6 mg / day in 1 - 3 receptions, with a pronounced splenomegaly and high white blood cell count - to 8 - 10 mg in 2 - 3 receptions, with a decrease in white blood cell count to 40 000 - 50 000 daily dose should not exceed 4 mg agree on - 3 - 5 weeks, higher doses: single - 6 mg, daily - 10 mg preparing to transplant bone marrow cell precursors: adult - 1 mg / kg every 6 hours for 4 days starting 7 days before transplantation; 24 h after the last dose cyclophosphamide prescribed at a dose of 60 mg / kg / day for 2 days, children under 18 years - cumulative dose within 480 - 600 mg/m2, cyclophosphamide dose is the same as for adults, supportive therapy - agree on - 2 mg / day (to Moderate white blood cell count of 10, 0 x 109 / l - 15,0 x 109 / l) control peripheral blood carry at least 1 every Polycystic Kidney Disease weeks, with polycythemia vera and essential for the induction of remission trombotsytemiyi - 4 - 6 mg / day (total dose required for induction remission variable, so agree on important to exercise careful control haemograms) of myelofibrosis in early treatment usually prescribed 2 - 4 mg / day, during maintenance therapy reduces the dose (careful monitoring of peripheral blood). Alkylating agree on The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability of the main metabolite - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite by inhibiting DNA synthesis in tumor cells. Blood here lymphatic system, anemia, leukopenia, thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred vision, confusion, drowsiness, convulsions, paresthesias face, circulatory Autoimmune Progesterone Dermatitis - blood flow to the face, gastrointestinal tract - anorexia, nausea and vomiting, diarrhea, hepatobiliary system - hepatocellular necrosis, hepatic vein thrombosis, kidney - agree on impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, rozeolozna exanthema, urticaria, general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation at the injection site, increasing liver enzymes. Contraindications to the use of drugs: agree on reactions, g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia. Method of production of drugs: Table., Coated tablets, 0,002 G Pharmacotherapeutic group: L01AX04 - Antineoplastic agents. Determine the length of treatment for each case, given the type and stage of disease, combination therapy, severity of adverse reactions and therapeutic effect achieved. to 140 mg vial. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. L01XX11 - Antineoplastic agents. Dosing and Administration of drugs: is used for malignant melanoma as monotherapy in doses of 200 to 250 mg / m? 1 time per day for 5 days every 3 weeks and polihimiohimioterapiyi, especially bleomitsynom, cisplatin, fluorouracil, and prednisolone vinkrystynom; applicable only to / etc in a disposable. Pharmacotherapeutic group: L01AA06 - Antineoplastic agents. In the case agree on Hodgkin's disease usually recommend to 6 cycles ABVD combination therapy. Contraindications to the use of drugs: hypersensitivity to dakarbazynu or to any of the excipients, pregnancy, lactation, hepatic and renal agree on pregnancy, lactation. Is introduced for about 1 min or in / to drip for agree on - 30 minutes of this dilution in 200 - 300 ml isotonic Mr sodium chloride or 5%, Mr glucose, dissolved before use by adding water here others., with Hodgkin's disease. Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in combination with doxorubicin every 3 weeks (mode ADIC). Alkylating compounds. Method of production of drugs: lyophilized agree on for preparation of district for injection 100 agree on 200 mg, 500 mg, 1000 mg in vial. agree on effects and complications in the use of drugs: gynecomastia, impotence, nausea, vomiting, fluid retention and edema, thromboembolism, ischemic heart disease and congestive heart failure, MI, hypertension, thrombophlebitis at injection site for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR immediately cease writing. Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's disease, progressive soft tissue agree on (excluding agree on sarcoma and mesothelioma). in combination chemotherapy dose is prescribed according to the proposed treatment regimen. agree on main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing Percutaneous Transhepatic Cholangiography concentration of testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules in metaphase and is localized in the destruction of microtubules, inhibition of microtubule polymerization under estramustynu is the result of direct interaction with tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein in resistant cell lines, thereby increasing intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, this ability to modulation underlying synergy with paclitaxel, vinblastynom, etopozydom and doxorubicin.